Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05570721 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Depression, Aging, Stress and Heart Health Study

Study acronym: DASHH
StatusCompleted
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoints: details revised at 8 of 8 entries Trial completed · Final enrollment: 41 participants (planned 30) · Primary completion date changed from estimate of Jun 30, 2026 to Feb 25, 2025 · 3 more Show 6 more changesShow less
    • Trial completed
    • Final enrollment: 41 participants (planned 30)
    • Primary completion date changed from estimate of Jun 30, 2026 to Feb 25, 2025
    • Eligibility criteria expanded, about 14 words
    • Site details revised
    • Study description expanded, about 4 words
  2. Primary and study completion dates: Nov 15, 2025 to Jun 30, 2026v5
  3. Primary and study completion dates: Oct 5, 2024 to Nov 15, 2025v4
  4. Re-verified, no change to tracked fieldsv3
  5. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 5, 2022 to Nov 16, 2022 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Oct 5, 2022 to Nov 16, 2022
    • Site details revised
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Depression is a known risk factor for cardiovascular disease (CVD), and this comorbidity contributes significantly to the morbidity and mortality of women. The menopausal transition or perimenopause is a period of vulnerability for both depression and CVD, making it a key time to study this critical public health issue. This research will preliminarily explore whether disruption in two novel stress pathways 1) the renin-angiotensin-aldosterone system (RAAS) and autonomic nervous system (ANS) and their relationship may underlie the link between these illnesses. Findings will provide important insight into potential mechanisms by which depression during perimenopause may increase risk for CVD in midlife women, which will inform potential risk reduction and treatment strategies that can improve health outcomes in this population.
Trial Details
NCT Number NCT05570721
Lead Sponsor University of North Carolina, Chapel Hill
Collaborators: Foundation of Hope, North Carolina
Conditions Menopause, Depression, Heart Disease in Women, Stress
Enrollment 41 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov